This means that passive immunization with tau antibodies is actually a feasible therapeutic target and which the CSF degree of p-tau262/356 or of the microtubule binding area (MTBD) can serve as a useful biomarker of tau pathology to observe tau therapeutics in clinical trials. Aesthetics can als